Table 1.
Clinical and pathological characteristics of patients (a) 61 patients with non-muscle-invasive bladder cancer (NMIBC). (b) 67 patients with muscle-invasive bladder cancer (MIBC).
| No recurrence | Recurrence | Muscle-invasive progression | ||||
|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | p* | n (%) | p** | |
| Total population | 61 (100) | 19 (31.1) | 32 (52.5) | 10 (16.4) | ||
| Age (years) | ||||||
| ≥ 60 | 45 (73.8) | 13 (68.4) | 22 (68.8) | 0.98 | 10 (100.0) | 0.0095 |
| < 60 | 16 (26.2) | 6 (31.6) | 10 (31.2) | 0 (0.0) | ||
| Sex | ||||||
| Male | 54 (88.5) | 17 (89.5) | 28 (88.9) | 0.81 | 9 (90.0) | 0.70 |
| Female | 7 (11.5) | 2 (10.5) | 4 (11.1) | 1 (10.0) | ||
| Smoking status | ||||||
| Non-smoker | 27 (44.3) | 6 (31.6) | 16 (50.0) | 0.20 | 5 (50.0) | 0.96 |
| Smoker | 34 (55.7) | 13 (68.4) | 16 (50.0) | 5 (50.0) | ||
| History of NMIBC | ||||||
| No | 34 (55.7) | 16 (84.2) | 14 (43.7) | 0.0045 | 4 (40.0) | 0.45 |
| Yes | 27 (44.3) | 3 (15.8) | 18 (56.3) | 6 (60.0) | ||
| Cis associated | ||||||
| No | 58 (95.1) | 19 (100.0) | 31 (96.9) | 0.79 | 8 (80.0) | 0.015 |
| Yes | 3 (4.9) | 0 (0.0) | 1 (3.1) | 2 (20.0) | ||
| Grade | ||||||
| Low | 25 (41.0) | 10 (52.6) | 14 (43.8) | 0.48 | 1 (10.0) | 0.029 |
| High | 36 (59.0) | 9 (47.4) | 18 (56.2) | 9 (90.0) | ||
| Tumor stage | ||||||
| Ta | 39 (63.9) | 13 (68.4) | 23 (71.9) | 0.79 | 3 (30.0) | 0.015 |
| T1 | 22 (36.1) | 6 (31.6) | 9 (28.1) | 7 (70.0) | ||
| HRAS mutation£ | ||||||
| No | 42 (95.5) | 13 (92.9) | 21 (95.5) | 0.68 | 8 (100.0) | 0.80 |
| Yes | 2 (4.5) | 1 (7.1) | 1 (4.5) | 0 (0.0) | ||
| FGFR3 mutation£ | ||||||
| No | 22 (50.0) | 7 (50.0) | 11 (50.0) | 1.00 | 4 (50.0) | 1.00 |
| Yes | 22 (50.0) | 7 (50.0) | 11 (50.0) | 4 (50.0) | ||
| PIK3CA mutation££ | ||||||
| No | 50 (83.3) | 13 (72.2) | 28 (87.5) | 0.18 | 9 (90.0) | 0.53 |
| Yes | 10 (16.7) | 5 (27.8) | 4 (12.5) | 1 (10.0) | ||
| TERT mutation£ | ||||||
| No | 9 (20.5) | 4 (28.6) | 4 (18.2) | 0.46 | 1 (12.5) | 0.54 |
| Yes | 35 (79.5) | 10 (71.4) | 18 (81.8) | 7 (87.5) | ||
| Recurrence-free survival | Overall survival | |||||
|---|---|---|---|---|---|---|
| n (%) | n (%)a | p* | n (%)b | p* | ||
| Total population | 67 (100) | 46 (68.7) | 40 (59.7) | |||
| Age (years) | ||||||
| ≥ 60 | 49 (73.1) | 39 (79.6) | 0.001 | 34 (69.4) | 0.008 | |
| < 60 | 18 (26.9) | 7 (38.9) | 6 (33.3) | |||
| Sex | ||||||
| Male | 53 (79.1) | 34 (64.2) | 0.16 | 32 (60,4) | 0.83 | |
| Female | 14 (20.9) | 12 (85.7) | 8 (57.1) | |||
| Smoking status | ||||||
| Non-smoker | 15 (22.4) | 13 (86,7) | 0.09 | 12 (80.0) | 0.07 | |
| Smoker | 52 (77.6) | 33 (63.5) | 28 (53.8) | |||
| History of NMIBC | ||||||
| No | 40 (59.7) | 31 (77.5) | 0.06 | 25 (62.5) | 0.57 | |
| Yes | 27 (40.3) | 15 (55.6) | 15 (55.6) | |||
| Tumor stage | ||||||
| T2 | 25 (37.3) | 17 (68.0) | 0.93 | 10 (40.0) | 0.01 | |
| ≥ T3 | 42 (62.7) | 29 (69.0) | 30 (71.4) | |||
| N status | ||||||
| N- | 42 (62.7) | 25 (59.5) | 0.06 | 19 (45.2) | 0.002 | |
| N + | 25 (37.3) | 21 (84.0) | 21 (84.0) | |||
| HRAS mutation£ | ||||||
| No | 58 (98.3) | 38 (97.4) | 0.48 | 30 (96.8) | 0.43 | |
| Yes | 1 (1.7) | 1 (2.6) | 1 (3.2) | |||
| FGFR3 mutation£ | ||||||
| No | 53 (89.8) | 35 (89.7) | 0.97 | 28 (90.3) | 0.92 | |
| Yes | 6 (10.2) | 4 (10.3) | 3 (9.7) | |||
| PIK3CA mutation££ | ||||||
| No | 59 (88.1) | 41 (89.1) | 0.69 | 35 (87.5) | 0.86 | |
| Yes | 9 (13.5) | 5 (10.9) | 5 (12.5) | |||
| TERT mutation£ | ||||||
| No | 15 (25.4) | 8 (20.5) | 0.23 | 7 (22.6) | 0.60 | |
| Yes | 44 (74.6) | 31 (79.5) | 24 (77.4) | |||
*Chi-square test (Recurrence versus No recurrence); **chi-square test (Muscle-invasive progression versus the others).
£Information available for 44 patients; ££ Information available for 60 patients.
aFirst recurrence (local or metastatic); b Death; *chi-square test.
£Information available for 59 patients; ££ Information available for 67 patients.
Bold values are statistically significant (p < 0.05).